HemaCare Expands Development of Cellular Therapy Services by Bolstering Scientific Team with Two Strategic New Hires

Industry mavens strengthen HemaCare’s expertise in cell therapy and bioprocessing

LOS ANGELES--()--HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announced two new hires in senior leadership positions. Dr. Dominic Clarke joins the company as Global Head of Cell Therapy, and Dr. Brad Taylor arrives as Senior Product Manager. The expertise by both Dr. Clarke and Dr. Taylor will enhance HemaCare in the development of new products and services which support cell therapy and product lifecycle management.

“After a great start to the year and strong interest from partners, HemaCare is attracting unmatched talent and expanding its presence as the leading cell provider,” said Pete van der Wal, President and CEO. “These two new hires will enable HemaCare to serve both new and existing customers with uniquely developed product offerings and service solutions.”

Dr. Dominic Clarke joins the company in Los Angeles after previous positions held at Charter Medical and BioLife Solutions. At Charter Medical, Dr. Clarke successfully launched their first FDA 510(K) approved product for cell & gene therapy manufacturing use and was instrumental in positioning the company as a leading supplier to the industry. While at BioLife, Dr. Clarke led the research and development to support the critical role of biopreservation in maintaining viable, functional cell-based materials. With a Ph.D. in Cell and Molecular Biology from Binghamton University in New York and a postdoctoral fellowship in cell and developmental biology from SUNY Upstate Medical University, Dr. Clarke will offer scientific insight, product development strategy, and advanced support to HemaCare’s growing customer base.

"I am excited to join this established team and use my cell therapy and bioprocessing expertise to bring HemaCare’s high-quality cGMP cells into clinical projects across the globe," Dr. Clarke said. “HemaCare’s best-in-class human primary cells hold great potential to assist with the development of cell therapies, capable of treating a broad range of patients with cancer and other diseases.”

Dr. Brad Taylor, formerly a Product Manager at Perkin-Elmer, will manage the HemaCare product lifecycle strategy and work to maximize opportunities with existing products, as well as launch new products. Dr. Taylor holds a Ph.D. in Molecular Biology and Genetics from Friedrich-Alexander University in Germany and completed a postdoctoral fellowship in the department of surgical oncology at the University of Illinois at Chicago.

“From my initial interactions with Pete van der Wal and the team at HemaCare, I was impressed by their passion and commitment to simplifying researchers’ access to the highest quality cellular product,” said Dr. Taylor. “As a Scientist, I am aware first hand that good quality starting material is paramount for the acceleration of scientific findings and I look forward to working with the team and forward to being part of the solution.”

To learn more about HemaCare’s cell services and customizable products visit our website.

About HemaCare

HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory. Human biological material including peripheral blood, bone marrow, and cord blood is isolated into various primary cells types for fresh and frozen distribution. For 40 years, HemaCare has developed an extensive registry of repeat donors and provides human-derived primary blood cells and tissues for biomedical and drug discovery research and cell therapy clinical trials, and supports commercialization with apheresis collections, directly enabling customers to advance both autologous and allogeneic cellular therapies.

For more information please visit www.hemacare.com.

Contacts

HemaCare Media Contact:
Maria Thompson
1-619-722-0970
media.relations@apexthink.com
or
Business Development Contact:
Lou Juliano
631-521-9497
ljuliano@hemacare.com

Release Summary

HemaCare Expands Development of Cellular Therapy Services by Bolstering Scientific Team with Two Strategic New Hires

Contacts

HemaCare Media Contact:
Maria Thompson
1-619-722-0970
media.relations@apexthink.com
or
Business Development Contact:
Lou Juliano
631-521-9497
ljuliano@hemacare.com